Research spending post-MiFID ii: Is COVID-19 the straw that broke the camel's back?
from Enterprising Investor
The toxic cocktail of unanticipated consequences stemming from MiFID II research rules has a potent new ingredient: the coronavirus market drawdown. This may accelerate a regulatory review of MiFID II research rules in a post-Brexit Europe. While regulation takes time, the impact of MiFID II, combined with COVID-19, on the investment processes of US and European asset managers is unfolding in real time. The active equity strategies of European managers are at significant risk.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063